^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ASP2074

    i
    Other names: ASP2074
    Associations

    News

    Trials
    Company:
    Astellas
    Drug class:
    CD3 agonist, TSPAN-8 inhibitor
    Related drugs:
    Associations

    News

    Trials
    3ms
    A Study of ASP2074 in Adults With Solid Tumors (clinicaltrials.gov)
    P1, N=23, Active, not recruiting, Astellas Pharma Global Development, Inc. | Trial completion date: Dec 2027 --> Oct 2024 | Trial primary completion date: Sep 2027 --> Oct 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    ASP2074
    7ms
    A Study of ASP2074 in Adults With Solid Tumors (clinicaltrials.gov)
    P1, N=23, Active, not recruiting, Astellas Pharma Global Development, Inc. | Recruiting --> Active, not recruiting | N=193 --> 23
    Enrollment closed • Enrollment change • Metastases
    |
    ASP2074
    over1year
    A Study of ASP2074 in Adults With Solid Tumors (clinicaltrials.gov)
    P1, N=193, Recruiting, Astellas Pharma Global Development, Inc. | Trial primary completion date: Oct 2026 --> Sep 2027
    Trial primary completion date • IO biomarker • Metastases
    |
    CD8 (cluster of differentiation 8) • CA 19-9 (Cancer antigen 19-9)
    |
    ASP2074
    over1year
    A Study of ASP2074 in Adults With Solid Tumors (clinicaltrials.gov)
    P1, N=193, Recruiting, Astellas Pharma Global Development, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • IO biomarker • Metastases
    |
    CD8 (cluster of differentiation 8) • CA 19-9 (Cancer antigen 19-9)
    |
    ASP2074
    almost2years
    A Study of ASP2074 in Adults With Solid Tumors (clinicaltrials.gov)
    P1, N=193, Not yet recruiting, Astellas Pharma Global Development, Inc.
    New P1 trial • IO biomarker • Metastases
    |
    CD8 (cluster of differentiation 8) • CA 19-9 (Cancer antigen 19-9)
    |
    ASP2074